Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?

References

• Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Bulzebruck H, Bopp R, Drings P et al. New aspect in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer70, 1102–1110 (1992).
   PubMedGoogle Scholar
• Socinski MA, Morris DE, Masters GA et al. Chemotherapeutic management of stage IV non-small-cell lung cancer. Chest123(Suppl. 1), S226–S243 (2003).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Chandra P et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Ramaligam S, Belani C. Systemic chemotherapy for advanced non-small-cell lung cancer: recent advanced and future directions. Oncologist13, 5–13 (2008).
   PubMedGoogle Scholar
• Shepherd FA. Second-line chemotherapy for non-small-cell lung cancer. Expert Rev. Anticancer Ther.3, 435–442 (2003).
   PubMedGoogle Scholar
• Langer C, Soria JC. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin. Lung Cancer11(2), 82–90 (2010).
   PubMed Web of Science ®Google Scholar
• Sculier JP, Moro-Sibilot D. First- and second-line therapy for advanced non-small-cell lung cancer. Eur. Respir. J.33(4), 915–930 (2009).
   PubMedGoogle Scholar
• Rossi A, Maione P, Colantuoni G et al. Recent developments of targeted therapies in the treatment of non-small-cell lung cancer. Curr. Drug Discov. Technol.6(2), 91–102 (2009).
   PubMedGoogle Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med.360(15), 1579 (2009).
   Google Scholar
• Provencio M, Sànchez A, Garrido P et al. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin. Lung Cancer11(2), 91–97 (2010).
   PubMed Web of Science ®Google Scholar
• Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology77(6), 400–410 (2009).
   PubMed Web of Science ®Google Scholar
• Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann. Oncol. (Suppl. 9), ix135–ix142 (2007).
   PubMedGoogle Scholar
• Socinski MA. The emerging role of biomarkers in advanced non-small-cell lung cancer. Clin. Lung Cancer3, 149–159 (2010).
   Google Scholar
• Hirsh V. Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr. Oncol.17(2), 13–23 (2010).
   PubMed Web of Science ®Google Scholar
• Korpanty G, Smyth E, Sullivan LA et al. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp. Biol. Med. (Maywood)235(1), 3–9 (2010).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAiL). Ann. Oncol.21(9), 1804–1809 (2011).
   Google Scholar
• Gridelli C, Maione P, Rossi A et al. The role of bevacizumab in the treatment of non-small-cell lung cancer: current indications and future developments. Oncologist12, 1183–1193 (2007).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previous treated non-small-cell lung cancer (INTEREST): a randomized Phase III trial. Lancet372, 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Socinski MA. Treatment paradigms for advanced stage non-small-cell lung cancer in the era of multiple lines of therapy. J. Thorac. Oncol.4(2), 243–250 (2009).
   PubMedGoogle Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18, 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J. Clin. Oncol.18, 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Quoix E, Lebeau B, Depierre A et al. Randomized, multicentre Phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer. Ann. Oncol.15, 38–44 (2004).
   PubMed Web of Science ®Google Scholar
• Gervais R, Ducolone A, Breton JL et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann. Oncol.16(1), 90–96 (2005).
   PubMed Web of Science ®Google Scholar
• Lai CL, Tsai CM, Chiu CH et al. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small-cell lung cancer. Jpn. J. Clin. Oncol.35(12), 700–706 (2005).
   PubMed Web of Science ®Google Scholar
• De Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small-cell lung cancer. Oncologist13(Suppl. 1), 14–20 (2008).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Di Maio M et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 Study. Br. J. Cancer91(12), 1996–2004 (2004).
   PubMed Web of Science ®Google Scholar
• Schuette W, Nagel S, Blankenburg T et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J. Clin. Oncol.23(33), 8389–8395 (2005).
   PubMed Web of Science ®Google Scholar
• Camps C, Massuti B, Jiménez A et al. Randomized Phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group Trial. Ann. Oncol.17(3), 467–472 (2006).
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F, Chiodini P et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol.25, 1377–1382 (2007).
   PubMed Web of Science ®Google Scholar
• Smit EF, Mattson K, von Pawel J et al. ALIMTA© (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann. Oncol.14, 455–460 (2003).
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of the pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist14(3), 253–263 (2009).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(21), 3543–3551 (2008).
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Belani CP. Recent advances in targeted therapy for non-small-cell lung cancer. Expert Opin. Ther. Targets11, 245–257 (2007).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Toschi L, Finocchiaro G et al. Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. Int. J. Biol. Markers22(1 Suppl. 4), S10–S23 (2007).
   PubMedGoogle Scholar
• Florescu M, Hasan B, Seymour L et al. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J. Thorac Oncol.3(6), 590–598 (2008).
   PubMedGoogle Scholar
• Clark GM, Zborowski DM, Santabarbara P et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin. Lung Cancer7(6), 389–394 (2006).
   PubMed Web of Science ®Google Scholar
• Rosell R, Taron M, Sanchez JJ et al. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol.3(3), 277–283 (2007).
   PubMedGoogle Scholar
• Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene28(Suppl. 1), S32–S37 (2009).
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol.23, 5900–5909 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.26(26), 4268–4275 (2008).
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med.353(2), 133–144 (2005).
   PubMed Web of Science ®Google Scholar
• Reck M, van Zandwijk N, Gridelli C et al. Erlotinib in advanced non-small-cell lung cancer: efficacy and safety findings of the global Phase IV Tarceva Lung Cancer Survival Treatment study. J. Thorac. Oncol.5(10), 1616–1622 (2010).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus BSC care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366, 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G et al. The functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J. Clin. Oncol.11, 570–579 (1993).
   PubMed Web of Science ®Google Scholar
• Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy – Lung (FACT-L) quality of life instrument. Lung Cancer12, 199–220 (1995).
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Fairclough DL et al. What is a clinical meaningful change on the Functional Assessment of Cancer Therapy – Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J. Clin. Epidemiol.55, 285–295 (2002).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol.24, 5034–5042 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordell R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase III INTEREST trial. J. Clin. Oncol.28(5), 744–752 (2010).
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med.2(1), e17 (2005).
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol.23, 5856–5858 (2005).
   PubMedGoogle Scholar
• Hirsch FR, Varella-Garcia M, Bunn P Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol.21, 3798–3807 (2003).
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361, 947–957 5 (2009).
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongpraser S et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol.29(21), 2866–28674 (2011).
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Sandler AB. Salvage therapy for advanced non-small-cell lung cancer: factors influencing treatment selection. Oncologist11, 655–665 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis G, Peake M, Aultman R et al. Cost–effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J. Int. Med. Res.38(1), 9–21 (2010).
   PubMed Web of Science ®Google Scholar
• Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-celllung cancer treated with docetaxel: a systematic review and meta-analysis. Br. J. Cancer100(3), 436–441; 66 (2009).
   PubMedGoogle Scholar
• Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol.24(24), 3831–3837 (2006).
   PubMed Web of Science ®Google Scholar
• Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist12(5), 610–621 (2007).
   PubMed Web of Science ®Google Scholar
• Sekine I, Ichinose Y, Nishiwaki Y et al. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized Phase III study (V-15–32) of gefitinib versus docetaxel. Ann. Oncol.20(9), 1483–1488 (2009).
   PubMed Web of Science ®Google Scholar
• William WN Jr, Gold KA, Kim ES. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann. Oncol.20(9), 1455–1457 (2009).
   PubMedGoogle Scholar
• Tassinari D, Drudi F, Lazzari-Agli L et al. Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice. Ann. Oncol.21(2), 428–429 (2010).
   PubMedGoogle Scholar
• Tassinari D, Scarpi E, Sartori S et al. Second-line treatments in non-small-cell lung cancer. A systematic review of literature and meta-analysis of randomized clinical trials. Chest135(6), 1596–1609 (2009).
   PubMedGoogle Scholar
• Vamvakas L, Agelaki S, Kentepozidis NK et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small-cell lung cancer (NSCLC): results of a randomized Phase III Hellenic Oncology Research Group trial. Presented at: ASCO Meeting. Chicago, IL, USA, 4–8 June 2010 (Abstract 7519).
   Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S et al. Erlotinib versus docetaxel or pemetrexed as second- line therapy in patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the Phase III TITAN study. Presented at: ASCO Meeting. Chicago, IL, USA, 4–8 June 2010 (Abstract LBOA5).
   Google Scholar
• Kwak EL, Bang YJ, Camidge DR et al. Anaplastinc lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med.363(18), 1693–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Cipriani NA, Abidoye OO, Vokes E et al. MET as a target for treatment of chest tumors. Lung Cancer63(2), 169–179 (2009).
   PubMed Web of Science ®Google Scholar
• Spicer JF, Rudman SM. EGFR inhibitors in non-small-cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol.5(4), 245–255 (2010).
   PubMed Web of Science ®Google Scholar
• Belani CP. The role of irreversible EGFR inhibitors in the treatments of non-small-cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer Invest.28(4), 413–423 (2010).
   PubMed Web of Science ®Google Scholar
• Bang Y, Kwak EL, Shaw AT et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol.28, 18S(Suppl.), (2010) (Abstract 3).
   Google Scholar
• Yang J. Shih, W. Su et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J. Clin. Oncol.28, 15S (2010) (Abstract 7521).
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung I). Ann. Oncol.21(Suppl. 8), viii1–viii12 (2010) (Abstract LBA1).
   Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J et al. Subgroup analysis of LUX-Lung 1: a randomized Phase III Trial of afatinib (BIBW 2992) plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib. Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, IL, USA, 10 December 2010.
   Google Scholar
• Jänne PA, Reckamp KL, Koczywas M. Efficacy and safety of PF-00299804 (PF299) in patiens (pt) with advanced NSCLC after failure of al least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, Phase II trial (Abstract no. 8063). J. Clin. Oncol.27 (2009).
   Google Scholar
• Spigel D, Ervin T, Ramlau R et al. Randomised multicenter double-blind placebo-controlled Phase II study evaluating MetMAb, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Abstract LBA15. Ann. Oncol.21(Suppl. 8), viii1–viii12 (2010).
   Google Scholar
• Sequist LV, Akerley WL, Brugger W et al. Final results from ARQ 197–209: a global randomized placebo-controlled Phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naive patients with advanced non-small-cell lung cancer (NSCLC). Ann. Oncol.21(Suppl. 8), viii122–viii161 (2010) (Abstract 363O).
   Google Scholar